These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 11256319

  • 1. [In vitro activity of trovafloxacin (CP-99,219) against 434 bacterial strains: comparative study with other fluoroquinolones].
    Tali-Maamar H, Tebbal S, Rahal K.
    Arch Inst Pasteur Alger; 1998; 62():52-61. PubMed ID: 11256319
    [Abstract] [Full Text] [Related]

  • 2. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
    Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():43-9. PubMed ID: 9222069
    [Abstract] [Full Text] [Related]

  • 3. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA, Huband MD, Gage JW, Yoder SL, Roland GE, Gracheck SJ.
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [Abstract] [Full Text] [Related]

  • 4. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA, Qadri SM, Ueno Y, Walters EA, Domenico P.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK, Liu EY, Cheng AF.
    Chemotherapy; 1999 Jun; 45(1):22-7. PubMed ID: 9876206
    [Abstract] [Full Text] [Related]

  • 8. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV, Ho DH, LeBlanc B, Streeter H, Dvorak T.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [Abstract] [Full Text] [Related]

  • 9. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA.
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [Abstract] [Full Text] [Related]

  • 10. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H.
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
    Verbist L, Verhaegen J.
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):683-5. PubMed ID: 8894581
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone.
    Cormican MG, Jones RN.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):204-11. PubMed ID: 8980783
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
    Endtz HP, Mouton JW, den Hollander JG, van den Braak N, Verbrugh HA.
    Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
    [Abstract] [Full Text] [Related]

  • 18. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
    Bowker KE, Wootton M, Holt HA, Reeves DS, MacGowan AP.
    J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC, Chin NX.
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [Abstract] [Full Text] [Related]

  • 20. The chemistry and biological profile of trovafloxacin.
    Brighty KE, Gootz TD.
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():1-14. PubMed ID: 9222064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.